SVT 1A710
Alternative Names: SVT-1A710Latest Information Update: 18 Oct 2020
At a glance
- Originator Servatus Biopharmaceuticals
- Class Anti-inflammatories; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 01 Oct 2020 Preclinical trials in Inflammatory bowel diseases in Australia before October 2020 (Servatus Biopharmaceuticals pipeline, October 2020)
- 01 Oct 2020 Preclinical trials in Ulcerative colitis in Australia before October 2020 (Servatus Biopharmaceuticals pipeline, October 2020)